ImmunityBio公司最新报告显示，在采用Anktiva®联合CAR-NK细胞疗法的复发性胶质母细胞瘤患者中，中位总生存期数据尚未达到可统计的终点。这一无化疗治疗方案不仅展现出延长生存期的潜力，更值得注意的是，患者先前存在的淋巴细胞减少症出现了显著逆转。
该疗法通过激活患者自身的免疫系统对抗肿瘤，为传统治疗手段效果有限的脑癌患者提供了新的希望。淋巴细胞计数的恢复表明免疫功能得到改善，这可能为提升抗肿瘤疗效奠定基础。
研究结果凸显了Anktiva®与CAR-NK联合疗法的双重优势：既可能延长生存期，又能逆转化疗常见副作用带来的免疫抑制状态。这一突破性进展为晚期脑癌治疗开辟了全新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.